London-based ViiV Healthcare has announced three-year results from its Sword-1 and Sword-2 trials. These trials evaluated viral suppression rates of...
Read More...
The post ViiV announces long-term positive results for Juluca combination appeared first on Pharmaceutical Technology.
Original Article: ViiV announces long-term positive results for Juluca combination